Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Gross Profit (2020 - 2025)

Maravai Lifesciences Holdings has reported Gross Profit over the past 6 years, most recently at $12.8 million for Q4 2025.

  • Quarterly results put Gross Profit at $12.8 million for Q4 2025, down 33.77% from a year ago — trailing twelve months through Dec 2025 was $34.0 million (down 68.62% YoY), and the annual figure for FY2025 was $34.0 million, down 68.62%.
  • Gross Profit for Q4 2025 was $12.8 million at Maravai Lifesciences Holdings, up from $5.7 million in the prior quarter.
  • Over the last five years, Gross Profit for MRVI hit a ceiling of $205.2 million in Q2 2022 and a floor of $5.7 million in Q3 2025.
  • Median Gross Profit over the past 5 years was $35.6 million (2023), compared with a mean of $82.8 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 600.03% in 2021 and later plummeted 87.51% in 2023.
  • Maravai Lifesciences Holdings' Gross Profit stood at $189.3 million in 2021, then dropped by 19.99% to $151.5 million in 2022, then plummeted by 74.23% to $39.0 million in 2023, then tumbled by 50.32% to $19.4 million in 2024, then tumbled by 33.77% to $12.8 million in 2025.
  • The last three reported values for Gross Profit were $12.8 million (Q4 2025), $5.7 million (Q3 2025), and $7.8 million (Q2 2025) per Business Quant data.